SCHEMBL23316599

SCHEMBL23316599

CC(c1ccc(F)cc1)n1c(Nc2ccc(OC(F)(F)F)cc2)nc2cc(CCC(=O)O)ccc21

nearest known ligand 0.60

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 20/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23621921 1.00 IDH1 (0.60) IDH1
SCHEMBL23316598 1.00 IDH1 (0.60) IDH1
SCHEMBL23316443 0.94 IDH1 (0.61) IDH1
SCHEMBL23316566 0.94 IDH1 (0.61) IDH1
SCHEMBL23316514 0.94 IDH1 (0.61) IDH1
SCHEMBL23316596 0.94 IDH1 (0.59) IDH1
SCHEMBL23621922 0.94 IDH1 (0.59) IDH1
SCHEMBL23316597 0.94 IDH1 (0.59) IDH1
SCHEMBL26655819 0.93 IDH1 (0.53) IDH1
SCHEMBL26661885 0.93 IDH1 (0.53) IDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3816158-B1 BENZIMIDAZOLE DERIVATIVES AND USE THEREOF AS IDH1 INHIBITORS KPC PHARMACEUTICALS INC (CN) 2023-10-25 EP disclosed
US-11407717-B2 Benzimidazole derivatives and use thereof as IDH1 inhibitors KPC PHARMACEUTICALS, INC. (CN) 2022-08-09 US disclosed
US-20210206728-A1 BENZIMIDAZOLE DERIVATIVES AND USE THEREOF AS IDH1 INHIBITORS KPC PHARMACEUTICALS, INC. (CN) 2021-07-08 US disclosed
EP-3816158-A1 BENZIMIDAZOLE DERIVATIVES AND USE THEREOF AS IDH1 INHIBITORS KPC Pharmaceuticals, Inc. (CN) 2021-05-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407717-B2 Benzimidazole derivatives and use thereof as IDH1 inhibitors IDH1, IDH3A, IDH2 IDH1 1/4885
US-20210206728-A1 BENZIMIDAZOLE DERIVATIVES AND USE THEREOF AS IDH1 INHIBITORS IDH1, IDH3A, IDH2 IDH1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.